Search

everythinglearnresearchcommunity

for

Search:↓

Using polymeric micelles to deliver spironolactone topically could improve wound healing in skin affected by glucocorticoids.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Peptide-based PROTACs show promise in targeting hard-to-treat proteins, especially for cancer therapy.

Malt1 protease is essential for regulatory T cell function and could be targeted to boost antitumor immunity.

FGF21 can help reduce skin inflammation caused by C. acnes.

Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.

The new gel improves treatment of tough skin infections.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

Ishige sinicola extract may help prevent muscle atrophy through its antioxidant and anti-inflammatory effects.

IL-17 inhibitors are more effective than methotrexate in preventing psoriatic arthritis in psoriasis patients.

Stilbamidine and hydroxystilbamidine inhibit enzyme release from lysosomes and have effects similar to cortisol and chloroquine.

Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.

The composition with carnitine, thioctic acid, and saw palmetto extract may effectively reduce inflammation in hair follicle cells.

JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.

Cardamonin may help treat oral cancer by promoting cell death and stopping cancer cell growth.

Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.

Adapalene, Diosmin, and Azelastine could be repurposed to treat onchocerciasis.

Janus kinase inhibitors are promising for treating scarring alopecia, but more research is needed for safety and personalized treatments.

Certain cancer drugs interact with skin bacteria to cause acne-like rashes.

Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.

Ruxolitinib can cause a delayed skin reaction on the nose.

Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.

Different sPLA2 enzymes affect immunity, skin and hair health, reproduction, and may be potential targets for therapy.

Certain natural compounds can block an enzyme linked to prostate enlargement and hair loss, showing potential for new treatments.

Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.

JAK inhibitors show promise for treating hair loss in alopecia areata but need more clinical trials to confirm safety and effectiveness.

Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

MC-1R is present in skin cells and may help reduce inflammation.

Promising cancer treatments were found, but the manufacturer closed.